Based on the Health Canada review of data on quality, safety, and effectiveness, Health Canada considers that the benefit/risk profile of GardasilTM is favourable for the prevention of infection caused by the HPV (Types 6, 11, 16, and 18) and the following diseases associated with these HPV types: cervical cancer, vulvar and vaginal cancer, genital warts (condyloma acuminata), cervical adenocarcinoma in situ (AIS), cervical intraepithelial neoplasia (CIN) grades 1, 2, and 3, vulvar intraepithelial neoplasia (VIN) grades 2 and 3, and vaginal intraepithelial neoplasia (VaIN) grades 2 and 3 in girls and women 9-26 years of age.
La Ministre de l'Emploi, Mme. LGiga-fren Giga-fren